CD19-话题@MedSci

#CD19#

61篇内容 | 1451人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183198, encodeId=26e3218319888, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a> <a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a> <a href='/topic/show?id=b2434060d8' target=_blank style='color:#2F92EE;'>#CAR-NK#</a>, objectTitle=Nat Med：临床研究表明靶向CD19的脐带血衍生CAR-NK细胞有望治疗多种B细胞恶性肿瘤, objectType=article, longId=809981, objectId=e37d809981bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240118/1705587350504_2185383.png, objectUrl=/article/show_article.do?id=e37d809981bc, replyNumber=0, likeNumber=15, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176308, encodeId=4ddc21e630896, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a> <a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a> <a href='/topic/show?id=febe1089e5e3' target=_blank style='color:#2F92EE;'>#AT101#</a>, objectTitle=Mol Cancer：1期临床试验表明一种新型CAR-T细胞疗法有望治疗B细胞非霍奇金淋巴瘤, objectType=article, longId=805123, objectId=1aec8051235f, topicUrl=null, isHasObj=0, objectCover=https://msimg.bioon.com/bioon-com/20231219/1702986161437_2185383.png, objectUrl=/article/show_article.do?id=1aec8051235f, replyNumber=0, likeNumber=8, createdTime=2023-12-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176072, encodeId=0f0b21e6072e0, content=<a href='/topic/show?id=11bee785311' target=_blank style='color:#2F92EE;'>#细胞因子释放综合征#</a> <a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a> <a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a> <a href='/topic/show?id=4e2640e283' target=_blank style='color:#2F92EE;'>#CAR-T细胞#</a>, objectTitle=Blood：第三代anti-CD19 CAR-T细胞在治疗B细胞非霍奇金淋巴瘤的1期临床试验中显示出疗效，并且没有神经毒性, objectType=article, longId=805122, objectId=90688051226b, topicUrl=null, isHasObj=0, objectCover=https://msimg.bioon.com/bioon-com/20231219/1702988396669_2185383.png, objectUrl=/article/show_article.do?id=90688051226b, replyNumber=0, likeNumber=29, createdTime=2023-12-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2097454, encodeId=9486209e454c0, content=这6名患儿在接受基于 <a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a><a href='/topic/show?id=da2941861af' target=_blank style='color:#2F92EE;'>#基因编辑#</a>的 <a href='/topic/show?id=b75e1049821b' target=_blank style='color:#2F92EE;'>#CAR-T 细胞治疗#</a>后，有4人在28天内病情缓解，这使他们能够接受<a href='/topic/show?id=804d10498382' target=_blank style='color:#2F92EE;'>#骨髓干细胞移植#</a>，已重建健康的免疫系统。在这4人中，2人分别在治疗后9个月和18个月后处于持续缓解期，但遗憾的是，另外2人在干细胞移植后复发。仅仅编辑<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>，治标不治本，这种效果应该能想得到的，主要治疗仍然是靠骨髓干细胞移植起作用吧。, objectTitle=STM：CRISPR基因编辑的通用型CAR-T，治疗儿童白血病临床试验结果发布, objectType=article, longId=745645, objectId=fe88e45645c4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202201029/1667057247828_5635644.png, objectUrl=/article/show_article.do?id=fe88e45645c4, replyNumber=0, likeNumber=81, createdTime=2022-10-30, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe88e45645c4, moduleTitle=STM：CRISPR基因编辑的通用型CAR-T，治疗儿童白血病临床试验结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe88e45645c4)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1416483, encodeId=305d1416483fc, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL, objectType=article, longId=735519, objectId=bdfbe3551900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdfbe3551900, replyNumber=0, likeNumber=41, createdTime=2022-08-12, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdfbe3551900, moduleTitle=Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdfbe3551900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416482, encodeId=24d014164822d, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Science Advances：单细胞分析揭示靶向CD19的CAR-T疗法复发的机制, objectType=article, longId=729835, objectId=92c6e29835d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92c6e29835d2, replyNumber=0, likeNumber=53, createdTime=2022-06-19, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92c6e29835d2, moduleTitle=Science Advances：单细胞分析揭示靶向CD19的CAR-T疗法复发的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92c6e29835d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416481, encodeId=78aa141648111, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, objectType=article, longId=728566, objectId=eb89e28566e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e28566e7, replyNumber=0, likeNumber=56, createdTime=2022-06-04, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e28566e7, moduleTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e28566e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416480, encodeId=a11d141648093, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效, objectType=article, longId=728112, objectId=d043e28112d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d043e28112d0, replyNumber=0, likeNumber=51, createdTime=2022-05-30, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d043e28112d0, moduleTitle=Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d043e28112d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416479, encodeId=e8f514164e90b, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, objectType=article, longId=301786, objectId=fb92301e86b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb92301e86b3, replyNumber=0, likeNumber=43, createdTime=2022-03-29, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb92301e86b3, moduleTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb92301e86b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416478, encodeId=e52b14164e8b7, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批, objectType=article, longId=293305, objectId=4f17293305d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f17293305d6, replyNumber=0, likeNumber=57, createdTime=2022-01-04, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f17293305d6, moduleTitle=国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f17293305d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416477, encodeId=32ea14164e753, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, objectType=article, longId=220543, objectId=20ce220543ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20ce220543ab, replyNumber=0, likeNumber=52, createdTime=2021-11-19, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20ce220543ab, moduleTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20ce220543ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416476, encodeId=872114164e68f, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, objectType=article, longId=217966, objectId=237d21e9664c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237d21e9664c, replyNumber=0, likeNumber=39, createdTime=2021-10-02, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237d21e9664c, moduleTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237d21e9664c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416475, encodeId=0fa014164e51c, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, objectType=article, longId=216567, objectId=da4821656e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da4821656e3b, replyNumber=0, likeNumber=39, createdTime=2021-09-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da4821656e3b, moduleTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da4821656e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416474, encodeId=d1e814164e459, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后, objectType=article, longId=216349, objectId=c86e216349f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86e216349f4, replyNumber=0, likeNumber=44, createdTime=2021-08-28, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86e216349f4, moduleTitle=Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86e216349f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416473, encodeId=ce3314164e3ea, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布, objectType=article, longId=215111, objectId=7ebf2151117e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ebf2151117e, replyNumber=0, likeNumber=48, createdTime=2021-08-02, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ebf2151117e, moduleTitle=Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ebf2151117e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416472, encodeId=885114164e29e, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, objectType=article, longId=214948, objectId=920821494873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920821494873, replyNumber=0, likeNumber=47, createdTime=2021-07-29, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920821494873, moduleTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920821494873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416471, encodeId=8f3714164e104, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=42, createdTime=2021-07-29, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416470, encodeId=79f914164e011, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, objectType=article, longId=213190, objectId=1a3a21319035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3a21319035, replyNumber=0, likeNumber=52, createdTime=2021-06-26, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3a21319035, moduleTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3a21319035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416469, encodeId=e0221416469fd, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, objectType=article, longId=211074, objectId=1a872110e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a872110e4ea, replyNumber=0, likeNumber=49, createdTime=2021-05-12, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a872110e4ea, moduleTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a872110e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416468, encodeId=b238141646894, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, objectType=article, longId=210741, objectId=5562210e411f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5562210e411f, replyNumber=0, likeNumber=47, createdTime=2021-05-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5562210e411f, moduleTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5562210e411f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤# #CD19# #CAR-NK#

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#CD19# #Car-T细胞疗法# #AT101#

2023-12-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#细胞因子释放综合征# #CD19# #神经毒性# #CAR-T细胞#

2023-12-20发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起这6名患儿在接受基于 #CRISPR##基因编辑#的 #CAR-T 细胞治疗#后，有4人在28天内病情缓解，这使他们能够接受#骨髓干细胞移植#，已重建健康的免疫系统。在这4人中，2人分别在治疗后9个月和18个月后处于持续缓解期，但遗憾的是，另外2人在干细胞移植后复发。仅仅编辑#CD19#，治标不治本，这种效果应该能想得到的，主要治疗仍然是靠骨髓干细胞移植起作用吧。

STM：CRISPR基因编辑的通用型CAR-T，治疗儿童白血病临床试验结果发布

2022-10-30

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL

2022-08-12

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Science Advances：单细胞分析揭示靶向CD19的CAR-T疗法复发的机制

2022-06-19

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究

2022-06-04

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效

2022-05-30

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效

2022-03-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批

2022-01-04

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良

2021-11-19

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药

2021-10-02

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性

2021-09-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后

2021-08-28

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布

2021-08-02

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤

2021-07-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解

2021-06-26

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法

2021-05-12

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM

2021-05-03

科室
- - 订阅+
  - 更多科室
工具
服务